Core Viewpoint - Tongce Medical (600763) shows a slight increase in stock price and mixed capital flow, indicating potential investor interest despite some outflows from major and retail investors [1][2]. Group 1: Stock Performance - As of December 26, 2025, Tongce Medical closed at 40.93 yuan, up 0.17% with a turnover rate of 0.87% and a trading volume of 38,700 lots, amounting to a transaction value of 159 million yuan [1]. - Over the past five days, the stock has experienced fluctuations in capital flow, with a net outflow of 21.4 million yuan from major investors on December 26, representing 13.49% of the total transaction value [2]. Group 2: Financial Metrics - Tongce Medical's total market capitalization is 18.308 billion yuan, with a net asset value of 4.703 billion yuan and a net profit of 514 million yuan [3]. - The company reported a year-on-year revenue increase of 2.56% for the first three quarters of 2025, with a total revenue of 2.29 billion yuan and a net profit of 514 million yuan [3]. - The company's gross margin stands at 41.69%, significantly higher than the industry average of 36.47%, and its net profit margin is 26.91%, compared to the industry average of 4.61% [3]. Group 3: Analyst Ratings - In the last 90 days, seven institutions have rated Tongce Medical, with four buy ratings and three hold ratings, indicating a generally positive outlook [4]. - The average target price set by analysts over the past 90 days is 52.88 yuan, suggesting potential upside from the current trading price [4].

从资金流向上来看，当日医疗服务板块主力资金净流出8.24亿元，游资资金净流入4129.99万元，散户资 金净流入7.83亿元。医疗服务板块个股资金流向见下表： 证券之星消息，12月26日医疗服务板块较上一交易日下跌0.21%，皓元医药领跌。当日上证指数报收于 3963.68，上涨0.1%。深证成指报收于13603.89，上涨0.54%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600721 | 自花医药 | 12.24 | 5.88% | 48.95万 | | 5.94亿 | | 301096 | 百诚医药 | 55.93 | 3.79% | 5.12万 | | 2.84亿 | | 000504 | *ST生物 | 9.20 | 3.25% | 2.70万 | | 2461.38万 | | 301201 | 诚达药业 | 41.95 | 0.84% | 6.37万 | | 2.72亿 | | 603259 | 药明康德 | 92.70 | 0. ...

Core Viewpoint - Tongce Medical (600763) reported a slight decline in stock price, with significant net outflows from major and retail investors, while the company showed modest revenue and profit growth in its recent financial report [1][2]. Financial Performance - For the first three quarters of 2025, Tongce Medical achieved a main revenue of 2.29 billion yuan, an increase of 2.56% year-on-year [2]. - The net profit attributable to shareholders reached 514 million yuan, reflecting a year-on-year growth of 3.16% [2]. - The company's net profit excluding non-recurring items was 509 million yuan, up 3.09% year-on-year [2]. - In Q3 2025, the company reported a single-quarter main revenue of 842 million yuan, a 2.34% increase year-on-year [2]. - The single-quarter net profit attributable to shareholders was 192 million yuan, up 2.31% year-on-year [2]. - The single-quarter net profit excluding non-recurring items was also 192 million yuan, reflecting a 1.85% year-on-year increase [2]. - The company's debt ratio stood at 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan [2]. - The gross profit margin was reported at 41.69% [2]. Market Activity - As of December 23, 2025, Tongce Medical's stock closed at 40.68 yuan, down 0.83%, with a turnover rate of 0.68% and a trading volume of 30,500 hands, amounting to a transaction value of 124 million yuan [1]. - On December 23, the net outflow of major funds was 14.64 million yuan, accounting for 11.77% of the total transaction value, while retail investors saw a net inflow of 23.13 million yuan, representing 18.59% of the total transaction value [1].

证券之星消息，截至2025年12月18日收盘，通策医疗(600763)报收于41.06元，上涨0.61%，换手率 0.87%，成交量3.89万手，成交额1.59亿元。 12月18日的资金流向数据方面，主力资金净流出1160.26万元，占总成交额7.28%，游资资金净流出 662.48万元，占总成交额4.16%，散户资金净流入1822.74万元，占总成交额11.43%。 近5日资金流向一览见下表： 通策医疗2025年三季报显示，前三季度公司主营收入22.9亿元，同比上升2.56%；归母净利润5.14亿 元，同比上升3.16%；扣非净利润5.09亿元，同比上升3.09%；其中2025年第三季度，公司单季度主营收 入8.42亿元，同比上升2.34%；单季度归母净利润1.92亿元，同比上升2.31%；单季度扣非净利润1.92亿 元，同比上升1.85%；负债率25.1%，投资收益4122.43万元，财务费用3192.82万元，毛利率41.69%。通 策医疗（600763）主营业务：医疗服务。 该股最近90天内共有7家机构给出评级，买入评级4家，增持评级3家；过去90天内机构目标均价为 52.88。 资金流向名词解释：指 ...

Core Viewpoint - Tongce Medical (600763) is focused on providing medical services as a dental healthcare group, emphasizing the significant potential of the domestic market in China [1] Group 1: Company Strategy - The company aims to deepen its presence in the domestic dental healthcare service market [1] - It is committed to strengthening its leading position in Zhejiang Province [1] - The company is steadily advancing its layout in key regions across the country [1]

Group 1 - The core viewpoint of the article is that Tongce Medical (600763) has disclosed its total number of shareholders, which is 98,000 as of December 10, 2025 [1] - The company emphasizes the importance of fair information access for all investors and states that future updates on shareholder numbers will be provided in its official periodic reports [1]

Core Viewpoint - Tongce Medical (600763) reported a slight decline in stock price, with a closing price of 40.25 yuan on December 15, 2025, down 0.57% [1] Financial Performance - For the first three quarters of 2025, Tongce Medical achieved a main revenue of 2.29 billion yuan, an increase of 2.56% year-on-year [2] - The net profit attributable to shareholders was 514 million yuan, up 3.16% year-on-year, while the net profit excluding non-recurring items was 509 million yuan, increasing by 3.09% year-on-year [2] - In Q3 2025, the company reported a single-quarter main revenue of 842 million yuan, a year-on-year increase of 2.34% [2] - The single-quarter net profit attributable to shareholders was 192 million yuan, up 2.31% year-on-year, and the net profit excluding non-recurring items was also 192 million yuan, increasing by 1.85% year-on-year [2] - The company's debt ratio stands at 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan [2] - The gross profit margin is reported at 41.69% [2] Market Activity - On December 15, 2025, the net inflow of main funds was 1.6042 million yuan, accounting for 1.15% of the total transaction amount, while retail funds saw a net inflow of 9.405 million yuan, making up 6.74% of the total transaction amount [1] - Conversely, speculative funds experienced a net outflow of 11.0092 million yuan, representing 7.89% of the total transaction amount [1] Analyst Ratings - In the last 90 days, seven institutions provided ratings for Tongce Medical, with four giving a "buy" rating and three an "increase" rating [2] - The average target price set by institutions over the past 90 days is 5.288 billion yuan [2]

Core Viewpoint - Tongce Medical (600763) reported a slight decline in stock price and mixed capital flow data, indicating potential investor caution despite modest revenue and profit growth in recent quarters [1][2]. Group 1: Stock Performance - As of December 11, 2025, Tongce Medical's stock closed at 40.42 yuan, down 1.85% with a turnover rate of 0.96% and a trading volume of 43,100 hands, resulting in a transaction amount of 176 million yuan [1]. - On December 11, the net outflow of main funds was 30.99 million yuan, accounting for 17.66% of the total transaction amount, while retail investors saw a net inflow of 22.60 million yuan, representing 12.88% of the total [1]. Group 2: Financial Performance - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, a year-on-year increase of 2.56%, and a net profit attributable to shareholders of 514 million yuan, up 3.16% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 842 million yuan, reflecting a 2.34% year-on-year increase, with a net profit of 192 million yuan, up 2.31% year-on-year [2]. - The company's debt ratio stands at 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan, while the gross profit margin is reported at 41.69% [2]. Group 3: Analyst Ratings - Over the past 90 days, seven institutions have provided ratings for Tongce Medical, with four giving a "buy" rating and three an "increase" rating [2]. - The average target price set by institutions in the last 90 days is 5.29 yuan [2].

Group 1 - The company announced the cancellation of Mr. Zhou Hui's position as employee representative supervisor [2] - Ms. Wang Weiqian was elected as the employee director of the company's tenth board of directors, with a term consistent with the tenth board [2] - The employee representative meeting took place on December 10, 2025 [2]

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Tongce Medical (600763), indicating a slight decline in stock price and mixed capital flow on December 10, 2025 [1][2] - As of December 10, 2025, Tongce Medical's stock closed at 41.18 yuan, down 0.77%, with a turnover rate of 1.01% and a trading volume of 45,300 hands, resulting in a transaction amount of 186 million yuan [1] - The capital flow data on December 10 shows a net outflow of 18.96 million yuan from main funds, accounting for 10.19% of the total transaction amount, while retail investors saw a net inflow of 10.10 million yuan, representing 5.43% of the total [1] Group 2 - In the third quarter of 2025, Tongce Medical reported a main revenue of 842 million yuan, an increase of 2.34% year-on-year, and a net profit attributable to shareholders of 192 million yuan, up 2.31% year-on-year [2] - The company's financial metrics for the first three quarters of 2025 include a total revenue of 2.29 billion yuan, a net profit of 514 million yuan, and a debt ratio of 25.1% [2] - The average target price set by institutions for Tongce Medical over the past 90 days is 52.88 yuan, with 4 buy ratings and 3 hold ratings from 7 institutions [2]